We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Evotec Signs Ion Channel Hit Identification Agreement with Almirall
News

Evotec Signs Ion Channel Hit Identification Agreement with Almirall

Evotec Signs Ion Channel Hit Identification Agreement with Almirall
News

Evotec Signs Ion Channel Hit Identification Agreement with Almirall

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Evotec Signs Ion Channel Hit Identification Agreement with Almirall"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Evotec AG has announced that it has entered into a collaboration with Almirall S.A., to identify small molecule modulators of an ion channel target, selected by Almirall, involved in respiratory diseases.

Evotec will apply its in-depth electrophysiology and ion channel pharmacology expertise, as well as its screening platform, for the identification and validation of novel modulators of the selected ion channel.

Dr Jorge Beleta, Director Discovery Strategy and Alliances of Almirall, commented: “We are impressed not only by Evotec’s ion channel drug discovery platform but more importantly by their track record of success and scientific understanding of this challenging class of targets. We believe that the Evotec technology and scientists will provide Almirall with the best chances of finding novel, high quality hits, ready for optimization.”

Dr Mario Polywka, COO of Evotec stated: “We are proud to have been selected by Almirall for this important project. We have invested significantly in our ion channel and electrophysiology platform and scientists in recent years, and this programme is further validation of the value we can bring to our partners. We look forward to collaborating with and supporting Almirall in their quest to find novel treatments to address respiratory diseases.”
Advertisement